A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL)
Status:
Completed
Trial end date:
2021-06-22
Target enrollment:
Participant gender:
Summary
The objective of this study are to evaluate the safety and tolerability of ABT-199
(venetoclax) in patients with advanced Cutaneous T cell lymphoma (CTCL). A secondary
objective is to explore clinical response to ABT-199 (venetoclax) in patients with advanced
CTCL.